GNI Group

2160.TSE

28.45 USD

-0.88

-3.00%

Overview

Last close

28.45 usd

Market cap

1.43B usd

52 week high

30.23 usd

52 week low

10.22 usd

Target price

27.62 usd

Valuation

P/E

N/A

Forward P/E

N/A

Price/Sales

8.9562

Price/Book Value

3.5849

Enterprise Value

1.35B usd

EV/Revenue

8.4978

EV/EBITDA

631.6924

Key financials

Revenue TTM

158.68M usd

Gross Profit TTM

120.29M usd

EBITDA TTM

-4.07M usd

Earnings per Share

-0.12 usd

Dividend

N/A usd

Total assets

456.11M usd

Net debt

-22.20M usd

About

GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs in Japan and internationally. The company offers Etuary for the treatment of idiopathic pulmonary fibrosis. It also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, the company involved in developing F351, which is in Phase III clinical trial for the treatment of liver fibrosis; and F573 that is in phase II for the treatment of acute on chronic liver failure, as well as Tamibarotene for the treatment of acute promyelocytic leukemia. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan.